2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Checkpoint Inhibitor, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Workforce, Adverse Events, Biological Processes, Metabolism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Value, Diseases, Bleeding and Clotting, Thromboembolism, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, AML, APL, Translational Research, MDS, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4505 Statin lipophilicity and cardiotoxicity after frontline anthracycline-based therapy for diffuse large B-cell lymphoma: A propensity score matched trinetx analysis

Dhruv Dhiren Mistry, MBBS, Sukul Khanna2, Rishit Gupta3, Varshini Srinivasan, MBBS4, Priyanshi Maurya, MBBS5, Aditya Khanijo6, Vishnu Sudhakaran, MD7, Sawsan El sweilmein, MD8
1 Boston Medical Center, Boston, United States
2 University of Missouri - Kansas City (UMKC) School of Medicine, KANSAS CITY, United States
3 University College of Medical Sciences, New Delhi, New Delhi, India
4 University of Missouri - Kansas City (UMKC) School of Medicine, KANSAS CITY, United States
5 University of Missouri - Kansas City (UMKC) School of Medicine, KANSAS CITY, United States
6 Saint Vincent Hospital, Worchester, United States
7 University of Missouri - Kansas City (UMKC) School of Medicine, KANSAS CITY, United States
8 University of Missouri - Kansas City (UMKC) School of Medicine, KANSAS CITY, United States

Background: Anthracycline-induced cardiotoxicity remains the dominant late cardiovascular effect of R-CHOP, the mainstay frontline regimen for Diffuse Large B-Cell Lymphoma (DLBCL). The STOP-CA trial demonstrated the role of atorvastatin in reducing anthracycline-associated cardiac dysfunction in lymphoma patients. However, it remains unknown whether lipophilic statins, which offer greater myocardial penetration and pleiotropic effects preclinically, provide superior clinical cardio protection compared to hydrophilic statins, in real-world DLBCL populations. We compared cardiotoxicity and mortality between patients exposed to lipophilic and hydrophilic statins before anthracycline-based treatment.

Methods: We queried the TriNetX Global Collaborative Network, comprising de-identified electronic health records across over 180 health care organizations. Eligible patients were adults (≥18 years) with newly-diagnosed DLBCL who received doxorubicin and rituximab on or after January 1, 2012. We excluded patients with pre-existing heart failure, cardiomyopathy, prior anthracycline exposure, or or concurrent solid tumors. The lipophilic statin cohort included patients exposed to atorvastatin during in the 12 months before index doxorubicin and no other statin exposure. The active comparator, hydrophilic statin cohort included patients exposed to pravastatin or rosuvastatin during the same period and not exposed to atorvastatin. Cohorts were matched 1:1 by propensity score for age, sex, race/ethnicity, hypertension, type 2 diabetes, dyslipidemia, chronic kidney disease, ischemic heart disease, obesity, nicotine dependence, and baseline use of beta-blockers, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers. Outcomes from days 1 to 730 after first doxorubicin exposure (index event) were incident acute heart failure (primary outcome), any heart failure, cardiomyopathy, and all-cause mortality. These outcomes were assessed by Kaplan-Meier analysis with Cox-derived hazard ratios and 95% confidence intervals (CIs). A pre-specified high-risk subgroup analysis was conducted in patients aged ≥65 years with baseline hypertension or ischemic heart disease.

Results: After matching, each cohort included 759 patients, and all standardized mean differences were below 0.05. Median follow-up was 730 days in the lipophilic cohort and 633 days in the hydrophilic cohort. New onset acute heart failure occurred in 34 (4.5%) versus 24 (3.2%) patients, respectively (HR, 1.38; 95% CI, 0.82-2.32; p = .229). Any heart failure occurred in 87 (11.5%) versus 70 (9.2%) patients (HR, 1.23; 95% CI, 0.90-1.68; p= .198), and cardiomyopathy occurred in 31 (4.1%) versus 20 (2.6%) patients (HR, 1.50; 95% CI, 0.86-2.64; P = .152). All-cause mortality favored Atorvastatin group but did not reach conventional statistical significance in the main cohort (17.3% vs 20.3%; HR 0.82; 95% CI 0.65-1.03; p=0.92). However, in the high-risk subgroup analysis of 848 matched pairs, Atorvastatin was associated with a statistically significant 20% reduction of all-cause mortality compared to hydrophilic statins (19.9% vs 24.1%; HR 0.80; 95% CI 0.65-0.98; p=.032), with no accompanying increase in the risk of acute heart failure (HR 1.29; 95% CI 0.82-2.05; p=0.247).

Conclusions: Among patients with DLBCL receiving R-CHOP, we observed no statistically significant differences in heart failure, cardiomyopathy, or mortality between those exposed to atorvastatin and those exposed to pravastatin or rosuvastatin. However, in vulnerable, high-risk elderly patients (≥65 years with cardiovascular comorbidities), atorvastatin provided a statistically significant survival advantage. These findings highlight the need for targeted, prospective trials evaluating lipophilic statins in high-risk DLBCL populations.

Dhruv Dhiren Mistry, MBBS: No relevant conflicts of interest to declare.